 we report on our third quarter 2019 financial results and discuss our plans for commercialization of cytisinicline. 
 we also provide an update on our ongoing regulatory discussions with the FDA. 
 finally, we provide an update on our ongoing discussions with potential commercialization partners.    
 # 1_#1 _ # 1_#1 _ =    # 1 1.25 in.125 in.25 in 